Lipum AB Logo

Lipum AB

Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.

LIPUM | ST

Overview

Corporate Details

ISIN(s):
SE0015660899 (+1 more)
LEI:
549300V7JL0004BHBD93
Country:
Sweden
Address:
Tvistevägen 48 C, 907 36 Umeå
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Lipum AB is a clinical-stage biopharmaceutical company specializing in the discovery and development of novel treatments for chronic inflammatory diseases. The company's lead candidate, SOL-116, is a first-in-class humanized antibody that offers a unique mechanism of action by targeting the protein bile salt-stimulated lipase (BSSL). Lipum's primary goal is to address unmet medical needs and improve the quality of life for patients suffering from conditions such as rheumatoid arthritis (RA). The company has successfully completed its First-in-Human (FIH) Phase I clinical trial for SOL-116, with findings supporting continued development towards a potential new therapy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Lipum AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Lipum AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Lipum AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-14 Peter Hovstadius Other Sell 2,000 28,260.00 SEK
2025-04-14 Peter Hovstadius Other Sell 1,500 22,770.00 SEK
2025-04-14 Peter Hovstadius Other Sell 1,500 21,030.00 SEK

Peer Companies

Company Country Ticker View
Clearmind Medicine Inc. Logo
Develops psychedelic-derived medicines for Alcohol Use Disorder and mental health conditions.
United States of America CMND
Clearside Biomedical, Inc. Logo
Developing therapies for back-of-the-eye diseases via proprietary suprachoroidal delivery.
United States of America CLSD
Clene Inc. Logo
Developing nanocrystal therapies for neurodegenerative diseases like ALS and MS.
United States of America CLNN
Climb Bio, Inc. Logo
Clinical-stage biotech developing monoclonal antibodies for immune-mediated diseases.
United States of America CLYM
CMG Pharmaceutical Co., Ltd. Logo
Develops and manufactures prescription drugs, specializing in Oral Thin Film (OTF) technology.
South Korea 058820
Cocrystal Pharma, Inc. Logo
Develops novel antiviral drugs for influenza, coronaviruses, norovirus, and hepatitis C.
United States of America COCP
Co-Diagnostics, Inc. Logo
Develops patented PCR solutions for accurate infectious disease diagnostics.
United States of America CODX
co.don AG Logo
Develops personalized cartilage cell transplants for minimally invasive joint repair.
Germany CNW
Coeptis Therapeutics Holdings, Inc. Logo
Develops cell therapy platforms for cancer, autoimmune, and infectious diseases.
United States of America COEP
COGNITION THERAPEUTICS INC Logo
Clinical-stage biopharma developing small-molecule drugs for Alzheimer's and dementia.
United States of America CGTX

Talk to a Data Expert

Have a question? We'll get back to you promptly.